Fortune 50 Pharma Company Decreases Compliance Risk with BP Logix
A Fortune 50 pharmaceutical company with over 130K employees was frustrated with its off the shelf publications planning software. Their legacy system wasn’t flexible enough to accurately capture regional variations, which made navigation difficult for end users globally.

Record extraction was onerous, and integrations were expensive. Debarment checks and authorship agreements were often missing due to the manual nature of their processes, increasing compliance risk. As a result, the company was forced to hire agencies to do compliance track-downs, dramatically increasing total cost of ownership. When they discovered that they were at risk of failing audits, they knew it was time for a change.
“We have never implemented a system as seamlessly as this one across the company.”

— Director, Global Commercial Strategy
Fortune 50 Pharmaceutical Company

Action

With the need for a change established, the company decided to explore building their solution from scratch. Ultimately, the custom build turned out to be too expensive and time consuming to realistically scale, which led them to evaluate the emerging low-code space as an option. Since the processes need to constantly adapt to changing regulatory and business requirements, using a low-code platform would provide the team with greater agility.

Finding a low-code solution that could handle the complexity of highly regulated workflows and specific requirements like collaborative editing across multiple publication formats was a challenge. The company eventually chose BP Logix because of their flexibility, ease of use and robust compliance capabilities. BP Logix not only met the stringent requirements, but could also easily integrate with other enterprise applications, resulting in more streamlined processes across the publication planning lifecycle.
Result

The BP Logix Publications solution was tailored to the company’s unique publications review process which made it more user friendly. The robust workflow management and audit tracking capabilities eliminated the need for manual reviews and greatly reduced compliance risk.

As a result of the newly designed solution, the time it took for submitting a publication for review was cut from several hours to minutes, which increased speed to market, critical in this highly competitive marketplace. In addition, the total cost of the new solution was 50% lower than its predecessor.

Finally, the use of the patented “Process Timeline” approach provides visibility to management on process metrics, bottlenecks, and how long each step in the publication process takes. The choice to transition to BP Logix was a resounding win, and continues to provide a competitive advantage for this Pharma giant.